Piper Sandler's Positive TEV-'749 Survey Results Support Overweight Rating on Teva Pharma
Thursday, 13 June 2024, 11:40
Summary:
Amidst a positive survey outcome, Piper Sandler stands by its Overweight rating on Teva Pharmaceuticals.
Research Findings:
The research results from the TEV-'749 survey reinforce the analyst's confidence in Teva's market prospects.
Investment Stance:
The continued bullish stance suggests promising growth potential for Teva Pharma in the near future.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.